Hemogenyx Pharmaceuticals annual ebitda
2020
2021
2022
2023
2024
2025
Hemogenyx Pharmaceuticals EBITDA Growth & History (HEMO)
Hemogenyx Pharmaceuticals's calculated EBITDA was −£8.9M for fiscal 2025.
View full Hemogenyx Pharmaceuticals company overviewHemogenyx Pharmaceuticals annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −£8.9M | −£15.0M | — |
| 2024 | 2024-12-31 | £6.0M | −£1.1M | −15.40% |
| 2023 | 2023-12-31 | £7.1M | £10.5M | — |
| 2022 | 2022-12-31 | −£3.4M | −£857,062 | — |
| 2021 | 2021-12-31 | −£2.6M | −£532,781 | — |
| 2020 | 2020-12-31 | −£2.0M | — | — |
Hemogenyx Pharmaceuticals ebitda trends
Over the last five fiscal years, Hemogenyx Pharmaceuticals's ebitda decreased from −£2.0M to −£8.9M, a change of −£6.9M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hemogenyx Pharmaceuticals source filings ↗Community posts
Hemogenyx loss widens on non-cash options charge despite lower underlying spending
Hemogenyx Pharmaceuticals ($HEMO) reported a first-half pretax loss of £6.56 million, widening from £5.01 million. Reported operating costs increased to £6.48 million, but the company attributed most of the rise to a £5.54 million non-cash ...
